Poseida Therapeutics, Inc. announced the appointment of Charles M. Baum to its board of directors, effective May 16, 2022. Additionally, the company announced the resignation of David Hirsch, from its board of directors, effective May 17, 2022. Dr. Baum is President, Head of Research and Development, and a member of the Board of Directors at Mirati Therapeutics Inc. Dr. Baum currently serves as Chairman of the Board at OncoMyx Therapeutics.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.055 USD | -0.16% | -9.55% | -9.96% |
05-14 | Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises | MT |
05-14 | Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.96% | 297M | |
+10.88% | 115B | |
+12.65% | 106B | |
-4.42% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-10.97% | 17.56B | |
-39.36% | 17.32B | |
+7.24% | 14.03B | |
+32.84% | 12.13B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Poseida Therapeutics Appoints Charles M. Baum to Board of Directors